Avingtrans Share News (AVG)

(Sharecast News) - Avingtrans said on Tuesday that its Adaptix subsidiary had received CE certification for the Adaptix Ortho350, its orthopaedic 3D imaging system, allowing the technology to be commercialised across UK and European healthcare markets.

The AIM-traded engineering group said the certification demonstrated that the Ortho350 met EU and UK safety, health and environmental protection requirements.

Adaptix, based at the Oxford University Science Park, develops low-dose 3D digital tomosynthesis imaging systems designed for point-of-care use.

It described the Ortho350 as a compact, mobile system developed for imaging upper and lower extremities, including hands, elbows, shoulders, knees and feet.

Avingtrans said it could provide high-resolution 3D X-ray imaging at a fraction of the radiation dose of traditional CT systems and at a lower cost, while giving clinicians clearer images than 2D X-ray systems, faster patient workflows and improved diagnostic confidence.

Adaptix already supplies its 3D imaging technology to veterinary and industrial non-destructive testing markets through its VetSA3D and NDT3D product lines.

Avingtrans said CE certification marked a major inflection point by opening the human imaging market in the UK and Europe, supporting potential revenue growth and commercial partnerships.

"Receiving our CE certificate for the Adaptix Ortho350 is a defining moment for the company in our mission to transform radiology," said Stuart Gall, chief executive of Avingtrans's medical and industrial imaging division.

"This approval enables us to bring truly disruptive, low dose 3D imaging directly to clinicians and patients in the UK and Europe.

"For our shareholders, this milestone unlocks significant commercial opportunities and accelerates our pathway toward scaled adoption in human healthcare."

At 1326 BST, shares in Avingtrans were up 2.42% at 655.49p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate